BTAI
BioXcel Therapeutics Inc is a clinical-stage biopharmaceutical company which is focused on drug development utilizing novel artificial intelligence (AI) to identify the next wave of medicines across neuroscience and immuno-oncology.
BioXcel Therapeutics, Inc. (BTAI) is rated C+ (2.6/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Profitability (B+); its weakest is Momentum (F).
Quantitative Factor Evaluation • Updated
Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms
Ratings of B- and above are for members.
Register free to see every rating — your first 2 weeks of Premium are on us.
Register — 2 weeks freeUnderlying Financial Metrics
Historical Factor Score Progression
| Date | Value | Growth | Profitability | Momentum | Revisions | Overall |
|---|---|---|---|---|---|---|
| 2026-09-08 | C+ (2.7) | B+ (3.6) | B+ (3.8) | F (0.6) | C (2.2) | C+ (2.6) |
| 2026-09-01 | C+ (2.7) | B+ (3.6) | B+ (3.8) | F (0.5) | C (2.2) | C+ (2.5) |
| 2026-08-25 | B- (2.9) | B- (2.9) | D (1.4) | D- (0.9) | C- (2.0) | C- (2.0) |
| 2026-08-18 | B- (2.9) | B- (2.9) | D (1.4) | D (1.2) | C- (2.1) | C- (2.1) |
| 2026-08-05 | C+ (2.7) | C+ (2.7) | D (1.3) | C (2.4) | C- (1.9) | C (2.2) |